1359 ET - CoreWeave is likely to have more capital expenditures in 2027 than consensus estimates suggest, Truist analysts say in a note. "We don't see a scenario in which the company would maintain flat to slightly higher capex next year, with this level of ramp needed, especially with rising component costs," they say. But while shares are trading lower on CoreWeave's revised 2026 CapEx outlook, the analysts believe that the company's multi-year, take-or-pay contracts insulate it from bearing the brunt of component inflation. "Margin guidance and commentary around rising component costs likely fed into investor fears, but we see minimal risk to CoreWeave's business model as the company is able to pass through these costs," they write. CoreWeave drops 12%. (elias.schisgall@wsj.com)
(END) Dow Jones Newswires
May 08, 2026 13:59 ET (17:59 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments